MHRA-100788-PIP01-22

Key Facts

Active Substance
  • favezelimab
  • PEMBROLIZUMAB
Invented Name
Not availble at present
PIP Number MHRA-100788-PIP01-22
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Concentrate for solution for infusion
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
Conditions / Indications:
  • Treatment of Hodgkin lymphoma
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):favezelimabPEMBROLIZUMAB.pdf
Published Date 24/08/2023